R&D projects

HIPRA actively participates in a range of European research and innovation projects focused on advancing vaccines and biologics to address current and future health challenges.

Through collaboration with leading international partners, research institutions and public organisations, HIPRA contributes to cutting-edge initiatives that strengthen scientific knowledge, improve vaccine manufacturing capabilities and enhance preparedness for emerging health threats.

Supported by European programmes such as EU4Health and Horizon Europe, these projects contribute to building more resilient healthcare systems and reinforcing Europe’s capacity to ensure health security.

Explore HIPRA’s European R&D projects and discover the different initiatives and their specific objectives.

SPEEDCELL Project

The SPEEDCELL project is a European Union co-funded initiative led by HIPRA and supported by HaDEA, aiming to accelerate and optimise the development and manufacturing of vaccines and biologics. The project aims to enable a rapid, reliable and scalable response to global health emergencies within 100 days.

Learn more

RBDCOV Project

The RBDCOV project is a Horizon Europe initiative in which HIPRA leads the evaluation of the efficacy, safety and tolerability of its recombinant COVID-19 vaccine in children, adolescents and immunocompromised people. The project aims to provide broad and long-lasting protection against severe COVID-19.

Learn more

RSV Vaccine Project

The RSV vaccine project (research on a new vaccine for human respiratory disease (VSRVAC) is part of the “Misiones Ciencia e Innovación” programme. HIPRA collaborates with Polypeptide Therapeutic Solutions and Nostrum Biodiscovery to develop a new vaccine against respiratory syncytial virus (RSV), a major cause of respiratory infections worldwide.

Learn more

LWNVIVAT Project

The LWNVIVAT project is a European research initiative coordinated by Fundació Privada Institut de Recerca de la Sida-Caixa (IRSICAIXA), with HIPRA as a participating partner. It aims to develop effective vaccines and therapies against West Nile virus (WNV), an emerging pathogen with no approved human vaccine or specific treatment currently available.

Learn more